FDA’s approval of Amgen’s osteoporosis treatment, Prolia (denosumab), came with strings attached. Postmarket surveillance requirements – including Phase IV trials and studies – are increasingly part of the FDA approval pathway in the 21st century. There are a number of reasons for this, including … Continue reading at ComplianceZen.com →
From the Blog
Lowering Liability Risks with Supplier Qualification
FDA Compliance Training – Free Consulting?
From the NIH – Biotechnology Landscape 2020
FDA Forecast for 2012
From the PCP Council Science Symposium
Client Success Stories
“Cerulean's managing director immediately understood our needs and the agency's worries, and gave us a quick turn-around time. He was instrumental in creating a better solution and saving us.”
- Madeline Snow, Director, Lowell, Massachusetts
